Replies to post #26918 on Marker Therapeutics Inc (MRKR)

[Phantom Lord]

I think too many people forget this. Obviously the PC data is a big focus right now for traders but but until the end of December this was on no ones radar. Not even Marker's. The research reports and price targets were all based on the blood cancer trial. If the data is bad, and I would bet my left testicle that it is not, we will definitely see a drop from the traders but long term it shouldn't have any negative effects on the value of Marker.

[microcapbiotech]

Many things are very binary, like supply and demand, or risk versus reward.
As you say, the potential risk in MRKR is VERY LOW and the potential reward is VERY, VERY, VERY HIGH.

Seems like a NO BRAINER to me right now.
As much as QCOM, NVDA, and ALNY were no brainers at the time.